Explore Exelixis' strong Q1 2025 performance, with growth in CABOMETYX, expanded financial guidance, and progress in oncology innovation.

We have a session with Microbix to discuss the Q2 results they put out this morning. You can find those on the company's website on SEDAR and the press release probably was sent to your inbox. Let's ...

PRESS RELEASEAB SCIENCE PRESENTS ITS FINANCIAL INFORMATION AS OF DECEMBER 31, 2024 AND THE KEY EVENTS OF THE PERIOD Financial and corporate situation Operating deficit of 6,1 million euros as of ...

HHS “remains committed” to advancing cancer research, spokesperson Andrew Nixon said in an email. “HHS deeply values cancer research and remains committed to advancing life-saving scientific ...

Federal health overhaul HHS “remains committed” to advancing cancer research, spokesperson Andrew Nixon said in an email. “HHS deeply values cancer research and remains committed to ...

Roche/Genentech’s Tecentriq represents the best value for money among the new generation of immunotherapy treatments for lung cancer – but is still overpriced. That’s the conclusion of ...

Background: This work evaluated algorithmic bias on biomarkers using electronic pathology reports of female breast cancer across five subgroups: National Cancer Institute Surveillance, Epidemiology, ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Value investors seek out unheralded companies with excellent balance sheets and price ratios. Value stocks, then, are cheap stocks. But, cheap doesn’t mean “easy to deal with” nor does it ...